PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - 'Nanobiotix” or the 'Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the launch, subject to market and other conditions, of an approximately €75 million global follow-on offering (representing approximately $87 million) consisting of (i) a public offering of its American Depositary Shares ('ADSs”), each ADS representing one ordinary share, €0.03 nominal value per share (each an 'Ordinary Share”), of the Company, in the United States (the 'U.S. Offering”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares (the 'PFW”), exclusively addressed to 'qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the 'Prospectus Regulation”), and certain other countries (excluding the United States and Canada) (the 'International Offering”). The U.S. Offering and the International Offering are referred to, together, as the 'Global Offering”. The number of ADSs and Ordinary Shares issued in the Global Offering may be increased in the event of significant demand.